AR105434A1 - Proceso para preparar pridopidina - Google Patents

Proceso para preparar pridopidina

Info

Publication number
AR105434A1
AR105434A1 ARP160102219A ARP160102219A AR105434A1 AR 105434 A1 AR105434 A1 AR 105434A1 AR P160102219 A ARP160102219 A AR P160102219A AR P160102219 A ARP160102219 A AR P160102219A AR 105434 A1 AR105434 A1 AR 105434A1
Authority
AR
Argentina
Prior art keywords
pridopidine
base
composition
free
prepare
Prior art date
Application number
ARP160102219A
Other languages
English (en)
Inventor
Nguyen Ba
Olof Ingemar Vu - Bergh Anders
Yosef Mizrahi Orel
Gottesfeld Ronen
Lidor-Hadas Ramy
Barel Offir
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of AR105434A1 publication Critical patent/AR105434A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicación 1: Pridopidina caracterizada porque es pridopidina base en forma sólida. Reivindicación 2: Una composición que comprende la pridopidina base de la reivindicación 1; o una composición que comprende pridopidina base, caracterizada porque la composición está libre de alcohol isopropílico, o donde la composición esta libre de cloruro o libre de clorhidrato de pridopidina. Reivindicación 4: Un proceso para preparar pridopidina base sólida caracterizado porque comprende a) obtener una solución que comprende pridopidina base, y b) precipitar pridopidina base de la solución para formar pridopidina base sólida.
ARP160102219A 2015-07-22 2016-07-21 Proceso para preparar pridopidina AR105434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562195756P 2015-07-22 2015-07-22

Publications (1)

Publication Number Publication Date
AR105434A1 true AR105434A1 (es) 2017-10-04

Family

ID=57834816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102219A AR105434A1 (es) 2015-07-22 2016-07-21 Proceso para preparar pridopidina

Country Status (10)

Country Link
US (1) US10047049B2 (es)
EP (1) EP3325443B1 (es)
AR (1) AR105434A1 (es)
CA (1) CA2993607C (es)
DK (1) DK3325443T3 (es)
ES (1) ES2922991T3 (es)
HU (1) HUE059158T2 (es)
PL (1) PL3325443T3 (es)
TW (1) TW201718491A (es)
WO (1) WO2017015609A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9907786B2 (en) * 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA3015512C (en) 2016-02-24 2024-01-16 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
WO2018039477A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
EP3503890A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
EP3357909A1 (en) * 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
CA3072882C (en) 2017-08-14 2023-03-21 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
AU2018326596B2 (en) 2017-08-30 2021-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT
WO2023214412A1 (en) * 2022-05-03 2023-11-09 Prilenia Neurotherapeutics Ltd. Processes and intermediates for the preparation of pridopidine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641320B1 (en) 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
MX2007004216A (es) 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
CN101056854B (zh) * 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
RU2470013C2 (ru) 2007-04-12 2012-12-20 НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
CN103958469B (zh) * 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
AU2013323133A1 (en) 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease
IN2015DN03219A (es) 2012-09-27 2015-10-02 Teva Pharma
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
ES2911800T3 (es) 2014-01-22 2022-05-20 Prilenia Neurotherapeutics Ltd Formulaciones de liberación modificada de pridopidina
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use

Also Published As

Publication number Publication date
HUE059158T2 (hu) 2022-10-28
CA2993607C (en) 2024-01-16
US10047049B2 (en) 2018-08-14
US20170022158A1 (en) 2017-01-26
EP3325443A1 (en) 2018-05-30
EP3325443A4 (en) 2019-01-16
CA2993607A1 (en) 2017-01-26
TW201718491A (zh) 2017-06-01
ES2922991T3 (es) 2022-09-22
DK3325443T3 (da) 2022-07-18
PL3325443T3 (pl) 2022-08-01
EP3325443B1 (en) 2022-06-08
WO2017015609A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
AR105434A1 (es) Proceso para preparar pridopidina
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2018001030A1 (es) Productos alimenticios a base de carne..
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
AR102203A1 (es) Composiciones para el cuidado oral que comprenden zinc, arginina y serina
CL2015002309A1 (es) Proceso de fabricacion de vortioxetina.
ECSP17059101A (es) Composición ácida a base de leonardita y aminoácidos
AR101368A1 (es) Forma cristalina de sofosbuvir y proceso para su preparación
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
AU365182S (en) CPU holder
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.
CL2019003571A1 (es) Lipido que comprende ácido docosapentanoico. (divisional solicitud 3351-2016)
CL2018003692A1 (es) Composición cosmética anti-envejecimiento, uso de la composición y método para tratamiento anti-envejecimiento.
UY37763A (es) 2,5-dibromopiridina y procesos para prepararla
CO2017005357A2 (es) Un proceso para la fabricación de idalopirdina
UY35715A (es) Proceso para preparar dronedarona y sales de la misma
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
CR20180110A (es) Libobactina para uso en el tratamiento de la mastitis bovina
CA168517S (en) Stand for shaver
UA114469U (xx) ЗАСТОСУВАННЯ ПРЕПАРАТУ КАПІКОРУ (МЕЛЬДОНІЮ ДИГІДРАТУ І γ -БУТИРОБЕТАЇНУ ДИГІДРАТУ) ЯК НЕФРОПРОТЕКТОРНОГО ЗАСОБУ